Health
Eli Lilly’s Stock Has Swung on Alzheimer’s Drug Developments. What Investors Need to Know. – Barron’s
Eli Lilly may have recently disappointed investors with a study’s data, but the approach being taken by it and other drugmakers to treat the disease seems to be…
When
Eli Lilly
presented the results of a small study of its Alzheimers disease therapy donanemab last weekend, investors were hoping for a miracle. It didnt materialize, and Lilly (ticker: LLY) shares, which had run up 11.7% when the company previewed the study back in January, slid 11.6% by the end of trading on Thursday.Those swings in the stock dont tell the real story of donanemab. The data that Lilly presented last Saturday were positive for Alzheimers drug development in general, and for…
-
General18 hours agoAustralian celebrity chef Peter Russell-Clarke dies aged 89
-
Noosa News23 hours agoSouth-west Queensland highway closed after truck carrying oxygen cylinders catches fire
-
Noosa News18 hours agoWoman airlifted to Brisbane hospital after big cat mauling at south-east Queensland zoo near Toowoomba
-
Noosa News18 hours agoUnvaccinated horse dies from Hendra virus as Queensland records first case in three years